Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the…
| From | National Institutes of Health |
|---|---|
| Who can apply | state governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types |
| Eligibility notes | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or… |
| How much | Amount not stated |
| Deadline | Thu, Jan 7, 2027 (76 days left) |
| Category | Education, Health |
| Type | Grant |
| Opportunity # | PAR-25-070 |
| Assistance listing | 93.393 |
| Posted | Mon, Nov 18, 2024 |